Mutant p53 as a guardian of the cancer cell

被引:0
|
作者
Fiamma Mantovani
Licio Collavin
Giannino Del Sal
机构
[1] AREA Science Park,Laboratorio Nazionale CIB (LNCIB)
[2] Università degli Studi di Trieste,Dipartimento di Scienze della Vita
[3] IFOM—the FIRC Institute of Molecular Oncology,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.
引用
收藏
页码:199 / 212
页数:13
相关论文
共 50 条
  • [21] Guardian of corpulence: a hypothesis on p53 signaling in the fat cell
    Bazuine, Merlijn
    Stenkula, Karin G.
    Cam, Maggie
    Arroyo, Mathilde
    Cushman, Samuel W.
    CLINICAL LIPIDOLOGY, 2009, 4 (02) : 231 - 243
  • [22] P53: guardian and suppressor of longevity?
    Donehower, LA
    EXPERIMENTAL GERONTOLOGY, 2005, 40 (1-2) : 7 - 9
  • [23] p53: Guardian of cellular senescence
    WynfordThomas, D
    JOURNAL OF PATHOLOGY, 1996, 180 (02): : 118 - 121
  • [24] Targeting mutant p53 and cell-cell adhesion in ovarian cancer
    Iwanicki, Marcin P.
    Novak, Marian
    Zervantonakis, Ioannis K.
    Ince, Tan A.
    Drapkin, Ronny
    Brugge, Joan S.
    CLINICAL CANCER RESEARCH, 2013, 19
  • [25] Expression of mutant p53 affects cancer cell sensitivity to topotecan
    Mingaleeva, R.
    Sagdeeva, A.
    Sayarova, R.
    Bulatov, E.
    Miftakhova, R. R.
    Rizvanov, A. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] CANCER Mutant p53 and chromatin regulation
    Prives, Carol
    Lowe, Scott W.
    NATURE, 2015, 525 (7568) : 199 - 200
  • [27] The role of mutant p53 in human cancer
    Goh, Amanda M.
    Coffill, Cynthia R.
    Lane, David P.
    JOURNAL OF PATHOLOGY, 2011, 223 (02): : 116 - 126
  • [28] Mutant p53 as an Antigen in Cancer Immunotherapy
    Sobhani, Navid
    D'Angelo, Alberto
    Wang, Xu
    Young, Ken H.
    Generali, Daniele
    Li, Yong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (11) : 1 - 21
  • [29] Mutant p53 in cell-cell interactions
    Pilley, Steven
    Rodriguez, Tristan A.
    Vousden, Karen H.
    GENES & DEVELOPMENT, 2021, 35 (7-8) : 433 - 448
  • [30] Mutant p53 as a target for cancer treatment
    Duffy, Michael J.
    Synnott, Naoise C.
    Crown, John
    EUROPEAN JOURNAL OF CANCER, 2017, 83 : 258 - 265